Related Experiment Video
Updated: Jun 23, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Continuous dopaminergic stimulation achieved by duodenal levodopa infusion
Per Odin1, Erik Wolters, Angelo Antonini
1Department of Neurology, Central Hospital, Bremerhaven, Germany.
Summary
Duodopa, a levodopa/carbidopa-gel suspension delivered via intestinal infusion, offers continuous dopaminergic stimulation for advanced Parkinson's disease. This approach improves motor function and reduces "off" time compared to conventional treatments.
Area of Science:
- Neurology
- Pharmacology
- Gastroenterology
Background:
- Parkinson's disease (PD) management ideally requires continuous dopaminergic stimulation.
- Current treatments, including dopamine agonists, do not fully meet this need, especially in advanced stages.
- A continuous and strong dopaminergic stimulation remains an unmet therapeutic goal in advanced PD.
Purpose of the Study:
- To evaluate the efficacy and safety of levodopa/carbidopa-gel suspension (Duodopa) administered via continuous duodenal infusion.
- To assess the impact of Duodopa on motor fluctuations, "off" time, and overall functioning in advanced Parkinson's disease patients.
- To compare Duodopa's outcomes with conventional oral treatments.
Main Methods:
- Continuous infusion of levodopa/carbidopa-gel suspension directly into the duodenum using a portable pump.
- Clinical studies and retrospective analysis of long-term patient data.
- Assessment of plasmatic levodopa concentrations, motor function, "off" time, and adverse events.
Main Results:
- Duodenal infusion resulted in smoother levodopa plasmatic concentrations and continuous receptor stimulation.
- Significant improvements were observed in global functioning, walking ability, and reduction of "off" time compared to conventional treatment.
- A 5% decrease in the daily levodopa dose was noted during long-term follow-up.
- Pharmacological adverse events were similar to oral administration, with intestinal tube dislocation to the stomach being the most frequent technical issue.
Conclusions:
- Duodopa provides a viable strategy for continuous dopaminergic stimulation in advanced Parkinson's disease.
- Intestinal levodopa/carbidopa-gel infusion offers significant clinical benefits over conventional oral therapy.
- Duodopa demonstrates a favorable long-term safety and efficacy profile for managing advanced Parkinson's disease.
More Related Videos
06:40Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry (CIS-FSCV) to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine
Published on: April 23, 2020
05:51Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...